AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14624763
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH injections
Trial: 24477299
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of ethanol/d as gin or beer
Trial: 20570264
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol gel (0.06%)
Trial: 20570264
Drug: Oral tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tibolone (2.5 mg)
Trial: 16162191
Drug: Quality‐of‐Life Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality‐of‐Life Therapy (QOLT)
Trial: 11076820
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg) and vitamin B(12) (1 mg) daily (n=59)
Trial: 8805892
Drug: EMLA 1
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA 1 ml + GTN 2 mg
Trial: 8805892
Drug: EMLA 2
RxNorm normalized name: Vyfemla 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 2 ml + GTN 2 mg
Trial: 8805892
Drug: EMLA 2
RxNorm normalized name: Vyfemla 28 Day Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 2 ml only
Trial: 1634449
Drug: Ibudilast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (20 mg twice daily orally)
Trial: 25804039
Drug: ET 90
RxNorm normalized name: Ferralet 90
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET 90 mg four days or more a week
Trial: 25804039
Drug: ET 90
RxNorm normalized name: Ferralet 90
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET 90 mg 3 days or less a week
Trial: 22784436
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (n=200)
Trial: 15377968
Drug: Practice group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice group (serial administration of BESS)
Trial: 15377968
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no serial administration of BESS)
Trial: 2980956
Drug: Aspirin therapy
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin therapy (mean duration 357 days)
Trial: 2980956
Drug: Non-aspirin NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin NSAID therapy (mean duration 67 days)
Trial: 17298716
Drug: Vaginal capsules
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal capsules of 200 mg of micronized progesterone (Utrogestan), 3 times daily
Trial: 17298716
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone in gel (Crinone 8%), once daily
Trial: 11350327
Drug: Isoflurane through
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane through the agent‐saving device
Trial: 9542476
Drug: ABT-761 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-761 (50 to 200 mg/day)
Trial: 8993088
Drug: Gepirone ER
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone ER (10‐60 mg/day)
Trial: 8993088
Drug: Imipramine (50‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50‐300 mg/day)
Trial: 2400306
Drug: IOPL with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOPL with saline solution
Trial: 2400306
Drug: IOPL with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOPL with saline solution and 2 g of chloramphenicol succinate
Trial: 31385489
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic field (PEMF) therapy in addition to transcutaneous electrical nerve stimulation (TENS) and hot pack (HP) therapy
Trial: 31385489
Drug: Sham magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham magnetic field (without current flow) in addition to TENS and HP therapy
Trial: 25582795
Drug: Full participation
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full participation group (treatment) in the extension programme
Trial: 19054928
Drug: Sublingual-swallow immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.p.)/D. farinae (D.f) 50/50 extract
Trial: 9732884
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg)
Trial: 9732884
Drug: Digoxin (0.007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.007 mg/kg)
Trial: 9732884
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (Propafenone vs Digoxin)
Trial: 3338379
Drug: Educational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational group meetings with NIDDM patients, consisting of three weekly lessons presented by a physician, nurse, and dietitian once every 4 months.
Trial: 29595122
Drug: Fondaparinux (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux (1.5 mg/d) administered subcutaneously
Trial: 23231379
Drug: TM81 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM81 (6 g, three times daily for 12 weeks)
Trial: 23231379
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g, three times daily for 12 weeks)
Trial: 17475527
Drug: Novolizer (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novolizer (12 microg formoterol twice daily)
Trial: 17475527
Drug: Aerolizer (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerolizer (12 microg formoterol twice daily)
Trial: 17068305
Drug: No rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No rt-PA treatment
Trial: 12687029
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 microg daily propelled by HFA 134a
Trial: 12687029
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 microg daily propelled by CFCs 11 and 12
Trial: 11145492
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg daily
Trial: 2895628
Drug: Corticosteroid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (1 mg/kg/day) + Plasma exchange
Trial: 2895628
Drug: Corticosteroid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (1 mg/kg/day) + Plasma exchange + Cyclophosphamide (2 mg/kg/day for 1 year)
Trial: 31588477
Drug: Cold spray
RxNorm normalized name: Butane/Isobutane/Propane Topical application Spray [COLD SPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold spray
Trial: 14511278
Drug: Paroxetine hydrochloride
RxNorm normalized name: Paroxetine Hydrochloride
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine hydrochloride (up to 40 mg per day)
Trial: 10883742
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol 2.50 mg
Trial: 10200010
Drug: Levalbuterol 0.31
RxNorm normalized name: levalbuterol 0.31 mg/3 mL inhalation solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol 0.31 mg
Trial: 29716436
Drug: Cladribine Tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine Tablets 3.5 mg/kg
Trial: 12390315
Drug: Pneumococcal and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal and Haemophilus influenzae type b vaccines
Trial: 12390315
Drug: High activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High activity antiretroviral treatment (HAART)
Trial: 25482466
Drug: udenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: udenafil (50 mg) for 12 weeks
Trial: 25482466
Drug: placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (50 mg) for 12 weeks
Trial: 14996880
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of hyaluronic acid
Trial: 10340958
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection of placebo
Trial: 9382907
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.3 mg/kg twice daily
Trial: 9382907
Drug: Dexamphetamine (DEX)
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (DEX) 0.15 mg/kg twice daily
Trial: 7726306
Drug: Imipramine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (low dose: 0.5 mg/kg per day)
Trial: 7726306
Drug: Imipramine (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (medium dose: 1.5 mg/kg per day)
Trial: 7726306
Drug: Imipramine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (high dose: 3.0 mg/kg per day)
Trial: 7726306
Drug: Imipramine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (all doses)
Trial: 7726306
Drug: Imipramine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (high dose)
Trial: 29846843
Drug: Velmanase alfa
RxNorm normalized name: Velmanase alfa
DrugBank: Velmanase alfa (DB12374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velmanase alfa (VA) 1 mg/kg weekly for 52 weeks
Trial: 24733910
Drug: PROSTVAC-VF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROSTVAC-VF vaccine
Trial: 17181436
Drug: Pollinex® Quattro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pollinex® Quattro (allergy vaccine)
Trial: 8411909
Drug: Pirenzepine (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (20mg administered intravenously immediately after the operation and twice daily from postoperative day 1 until day 7)
Trial: 31779001
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (5 g/day of fish oil providing 1.9-2.2 g of eicosapentaenoic acid + 1.1 g of docosahexaenoic acid)
Trial: 20677841
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both manipulations
Trial: 16320099
Drug: Talampanel (TLP)
RxNorm normalized name: Talampanel
DrugBank: Talampanel (DB04982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talampanel (TLP) 75 mg single oral dose
Trial: 1934379
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) Q 4 hours
Trial: 1934379
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) Q 6 hours
Trial: 1934379
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) Q 8 hours
Trial: 1934379
Drug: Oral isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral isosorbide dinitrate (ISDN) t.i.d. (0, 6, 12, and 24 hours)
Trial: 6462116
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550 mg twice daily
Trial: 6462116
Drug: Diflunisal 500
RxNorm normalized name: diflunisal 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 500 mg twice daily
Trial: 27574287
Drug: Serum insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum insulin (quartile 4 vs. quartile 1)
Trial: 27574287
Drug: Serum insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serum insulin (CLD)
Trial: 25054436
Drug: Colesevelam 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.8 g/day
Trial: 19395357
Drug: Novel computer‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel computer‐administered measure for malingering detection
Trial: 17470380
Drug: Taribavirin 800
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taribavirin 800 mg QD
Trial: 17470380
Drug: Taribavirin 1200
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taribavirin 1200 mg QD
Trial: 17470380
Drug: Taribavirin 1600
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taribavirin 1600 mg QD
Trial: 17470380
Drug: Ribavirin 1000
RxNorm normalized name: ribavirin 1000 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 1000 mg QD
Trial: 17470380
Drug: Ribavirin 1200
RxNorm normalized name: ribavirin 1200 Dose Pack, 4 Unit Dose Packs, 14 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin 1200 mg QD
Trial: 17470380
Drug: Taribavirin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taribavirin (any dose)
Trial: 17470380
Drug: Ribavirin (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (any dose)
Trial: 9676028
Drug: AML-type chemotherapy
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AML-type chemotherapy
Trial: 8618802
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone stimulation tests (arginine, insulin, L-dopa)
Trial: 8618802
Drug: TSH samples
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TSH samples obtained hourly
Trial: 770152
Drug: Sulpiride (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (300 to 1,200 mg daily)
Trial: 770152
Drug: Perphenazine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perphenazine (12 to 48 mg daily)
Trial: 31931909
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) of rifampicin, isoniazid, and pyrazinamide
Trial: 24084213
Drug: Fimasartan 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 120 mg oral administration
Trial: 17949681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of imagery rescripting and in vivo exposure
Trial: 10344035
Drug: Sarulplase (70-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarulplase (70-80 mg intravenously, 20 mg bolus followed by 60 mg infusion over 1 hour)
Trial: 10344035
Drug: Sarulplase with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarulplase with heparin (5000 IU bolus)
Trial: 7858592
Drug: Azathioprine (AZA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (AZA; initial daily dose 1 mg/kg)
Trial: 7858592
Drug: Methotrexate (MTX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (MTX; initial weekly dose 7.5 mg)
Trial: 31614332
Drug: 7-day daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day daily upper-arm remote ischaemic preconditioning (rIPC) (4 × 5 min 220 mmHg, interspaced by 5-min reperfusion)
Trial: 31614332
Drug: 7-day daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day daily upper-arm remote ischaemic preconditioning (rIPC)
Trial: 28500244
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day for 2 weeks)
Trial: 28500244
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV; 2 mg/day for 2 weeks)
Trial: 19860783
Drug: Reduced fluence
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced fluence photodynamic therapy (RPDT) + intravitreal triamcinolone acetonide (IVTA) (n = 20)
Trial: 19860783
Drug: Standard photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard photodynamic therapy (SPDT) + intravitreal triamcinolone acetonide (IVTA) (n = 20)
Trial: 19429918
Drug: Clopidogrel 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD)
Trial: 19429918
Drug: Prasugrel 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60 mg LD/10 mg MD
Trial: 7757318
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg pentaerithrityl-tetranitrate (PETN) as suspension
Trial: 7757318
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg pentaerithrityl-tetranitrate (PETN) as tablets
Trial: 6773532
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs (beta-blockers alone or in combination with thiazides)
Trial: 31779675
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation (2000 IU per day)
Trial: 23633272
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (300 mL for 5 days)
Trial: 23633272
Drug: 12% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% ethanol (300 mL for 5 days)
Trial: 21336580
Drug: Acute tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute tryptophan depletion (ATD) with 0 g of l-tryptophan
Trial: 21336580
Drug: Balanced condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced condition (BAL) with 1.21 g of l-tryptophan
Trial: 21336580
Drug: Acute tryptophan
RxNorm normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute tryptophan loading (ATL) with 5.15 g of l-tryptophan
Trial: 19586409
Drug: ASHMI 600
RxNorm normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASHMI 600 mg (2 capsules) twice daily for 1 week
Trial: 19586409
Drug: ASHMI 1200
RxNorm normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASHMI 1200 mg (4 capsules) twice daily for 1 week
Trial: 19586409
Drug: ASHMI 1800
RxNorm normalized name: JUNIPERUS ASHEI POLLEN
DrugBank: Juniperus ashei pollen (DB10460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASHMI 1800 mg (6 capsules) twice daily for 1 week
Trial: 19586409
Drug: ASHMI (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASHMI (all doses combined)
Trial: 17482302
Drug: Pre-treatment hemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment hemoglobin levels <12 g/dl
Trial: 17482302
Drug: Treatment less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment less radical than chemoradiation to 70 Gy
Trial: 7801739
Drug: Viloxazine (VLX,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine (VLX, 100 mg b.i.d. for 10 days)
Trial: 21170107
Drug: TCI remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI remifentanil with plasma concentration 4 μg/L and propofol (group B)
Trial: 21170107
Drug: TCI remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCI remifentanil with plasma concentration 7 μg/L and propofol (group C)
Trial: 21170107
Drug: TCI propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCI propofol and remifentanil (plasma concentration 4 μg/L) with infusion time longer than 4 hours (group D)
Trial: 19399385
Drug: Licensed pharmacological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed pharmacological smoking cessation agents
Trial: 19399385
Drug: Novel avenues
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel avenues of therapy
Trial: 15666959
Drug: Collaborative Care,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative Care, a structured depression treatment program that included planned, proactive and coordinated care with a health care team and informed, activated patients
Trial: 3311905
Drug: Cisapride (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (20 mg bid)